Evobrutinib (M2951) is a oral medication being evaluated for potential use in relapsing forms of multiple sclerosis and in secondary-progressive MS. The agent inhibits Bruton’s tyrosine kinase (BTK), an enzyme that regulates the function of B cells and macrophages, components of the immune system shown to play a role in MS.

A recent Phase 2 study examined how various doses of evobrutinib affected the total number of T1 gadolonium-enhancing lesions seen on magnetic resonance imaging (MRI) at weeks 12, 16, 20, and 24 of trearment. The study also assessed safety, the annualized relapse rate (ARR), and MRI findings at week 24 and 48 to read more on this click here https://mymsaa.org/news/new-in-ms-research-july-2019/#7